Evidence map›Paper›PMID 26897526›Full record

ArticleBreast cancer research : BCR2016

Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.

Joshua Ogony, Hye Joung Choi, Asona Lui, Massimo Cristofanilli, Joan Lewis-Wambi

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. An engineered niche delineates metastatic potential of breast cancer.Bioengineering & translational medicine · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Computational Tactics for Precision Cancer Network Biology.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Joshua OgonyDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA. jogony@kumc.edu.
Hye Joung ChoiDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA. halley522@hotmail.com.
Asona LuiDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA. alui@kumc.edu.
Massimo CristofanilliDepartment of Medical Oncology, Northwestern University, Chicago, IL, USA. massimo.cristofanilli@northwestern.edu.
Joan Lewis-WambiDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA. jlewis-wambi@kumc.edu.
The University of Kansas Cancer Center · USNorthwestern University · USUniversity of Kansas Medical Center · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Novel Approaches for the Control of Microbial PathogensP30GM103326 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI YANKEE, THOMAS M. · 2012 to 2016
$5.3M
The new biology of estrogen action in aromatase resistance breast cancer cellsK01CA120051 · NCI · FOX CHASE CANCER CENTER · PI LEWIS-WAMBI, JOAN SUEDEE · 2007 to 2011
$628k
Role of IFN inducible transmembrane protein 1 in AI-resistant breast cancerF30CA203160 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LUI, ASONA J · 2016 to 2019
$117k
NCI NIH HHS F30 CA203160NCI NIH HHS K01 CA120051NCI NIH HHS K01CA120051NCI NIH HHS P30 CA060553NIGMS NIH HHS P30 GM103326
6 · The paper itself

Abstract

backgroundInflammatory breast cancer (IBC) is a very aggressive and lethal subtype of breast cancer that accounts for about 4 % of all breast cancers diagnosed in the United States. Despite the efforts of several investigators to identify the molecular factors driving the aggressive phenotype of IBC, a great deal is still unknown about the molecular underpinnings of the disease. In the present study, we investigated the role of interferon-induced transmembrane protein 1 (IFITM1), a well-known interferon-stimulated gene (ISG), in promoting the aggressiveness of SUM149 IBC cells.

methodsWestern blot and real-time polymerase chain reaction analyses were performed to assess the protein and messenger RNA (mRNA) levels of IFITM1 and other ISGs in three IBC cell lines: SUM149, MDA-IBC-3, and SUM190. IFITM1 expression and cellular localization were assessed by using immunofluorescence, while the tumorigenic potential was assessed by performing cell migration, invasion, and colony formation assays. Small interfering RNA and short hairpin RNA knockdowns, enzyme-linked immunosorbent assays, and luciferase assays were performed to determine the functional significance of IFITM1 and signal transducers and activators of transcription 1 and 2 (STAT1/2) in SUM149 cells.

resultsWe found that IFITM1 was constitutively overexpressed at the mRNA and protein levels in triple-negative SUM149 IBC cells, but that it was not expressed in SUM190 and MDA-IBC-3 IBC cells, and that suppression of IFITM1 or blockade of the IFNα signaling pathway significantly reduced the aggressive phenotype of SUM149 cells. Additionally, we found that knockdown of STAT2 abolished IFITM1 expression and IFITM1 promoter activity in SUM149 cells and that loss of STAT2 significantly inhibited the ability of SUM149 cells to proliferate, migrate, invade, and form 2-D colonies. Notably, we found that STAT2-mediated activation of IFITM1 was particularly dependent on the chromatin remodeler brahma-related gene 1 (BRG1), which was significantly elevated in SUM149 cells compared with SUM190 and MDA-IBC-3 cells.

conclusionsThese findings indicate that overexpression of IFITM1 enhances the aggressive phenotype of triple-negative SUM149 IBC cells and that this effect is dependent on STAT2/BRG1 interaction. Further studies are necessary to explore the potential of IFITM1 as a novel therapeutic target and prognostic marker for some subtypes of IBCs.

Indexed as

Antigens, DifferentiationCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansInflammatory Breast NeoplasmsNeoplasm InvasivenessRNA, MessengerSignal TransductionSTAT2 Transcription FactorTranscriptional ActivationTriple Negative Breast NeoplasmsAntigens, Differentiationleu-13 antigenRNA, MessengerSTAT2 protein, humanSTAT2 Transcription Factor

Identifiers

PMID26897526
PMCPMC4761146
OpenAlexW2279605195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.